@mariovitali - This work is exciting...I'll keep following this thread! Thank you for answering my questions!
Doing metabolomics testing to understand one's individual biochemistry is essential. Having an understanding of one's genes, environmental exposures, etc. is critical, too. Then, a clever doctor can personalize a plan that meets the individual's needs.
We are all unique individuals with unique genes and environmental factors. It is pretty impossible for scientists to come up with sports of identical patients to run experiments are. We are not identical widgets.
Yes, I have hemachromatosis, and it has been treated. I had some other things, like chlamydia pneumoniae and heavy metal toxicity stressing my liver.
You make a good point that genetic conditions should be identified in individuals. I also have a lot of other interesting genes that may be impacting my situation, as other patients do, too.
As for curcumin, I have benefited in multiple situations from it. It has different mechanisms of action, which I have found to be extremely effective, and which are based on sound science. It is a COX-2 inhibitor, is a broad spectrum Phase II detoxifier, and has cancer-fighting properties. I have seen it reverse cancers that have been resistant to multiple chemo regimens. In my case, it has helped with removing toxic arsenic metabolites stuck halfway through the detox process. It has also calmed down brain and intestinal inflammation caused by intravenous immunoglobulins.
I suspect your network needs a few more data points to take into account all of my issues before recommending whether treatments that will or won't work. Real life is more complex than most studies.
This is why my doctors and I are individualizing my treatment, using knowledge of my genes, environmental exposures, and extensive lab work.
Curcumin (10-80 mg/kg, i.p.) dose dependently inhibited the immobility period, increased serotonin (5-hydroxytryptamine, 5-HT) as well as dopamine levels (at higher doses), and inhibited the monoamine oxidase enzymes (both MAO-A and MAO-B, higher doses) in mice.
Conclusion:
The study provides evidences for mechanism-based antidepressant actions of curcumin. The coadministration of curcumin along with piperine may prove to be a useful and potent natural antidepressant approach in the management of depression
@mariovitali thank you. But my question remains unanswered...how is a patient in scotland/U.K or anywhere else, a patient that is almost completely bedridden who crashes very easily going to find out what their unique regimen is? Who is going to test them? I know that in many countries gps run standard blood tests, that's it. We don't have access to the ME specialists in the U.S!!!
Dear Mr. VitaliA software exists that reads raw data from 23andme / MyHeritage and identifies specific SNPs. This software shows if the patient has problems in specific pathways such as Bile Acid Metabolism, Cholesterol Metabolism, Phagocytosis, Inflammation and more.
However this personalised regimen must first be evaluated by Medical Researchers. As soon as it is approved then all we need really is having the raw DNA data of each patient so that these issues may be identified for each case.
Pyruvate dehydrogenase complex and lactate dehydrogenase are targets for therapy of acute liver failure.
Abstract
BACKGROUND & AIMS:
Acute liver failure is a rapidly progressive deterioration of hepatic function resulting in high mortality and morbidity. Metabolic enzymes can translocate to the nucleus to regulate histone acetylation and gene expression.
METHODS:
Levels and activities of pyruvate dehydrogenase complex (PDHC) and lactate dehydrogenase (LDH) were evaluated in nuclear fractions of livers of mice exposed to various hepatotoxins including CD95-antibody, α-amanitin, and acetaminophen. Whole-genome gene expression profiling by RNA-seq was performed in livers of mice with acute liver failure and analyzed by gene ontology enrichment analysis. Cell viability was evaluated in cell lines knocked-down for PDHA1 or LDH-A and in cells incubated with the LDH inhibitor galloflavin after treatment with CD95-antibody. We evaluated whether the histone acetyltransferase inhibitor garcinol or galloflavin could reduce liver damage in mice with acute liver failure.
RESULTS:
Levels and activities of PDHC and LDH were increased in nuclear fractions of livers of mice with acute liver failure. The increase of nuclear PDHC and LDH was associated with increased concentrations of acetyl-CoA and lactate in nuclear fractions, and histone H3 hyper-acetylation. Gene expression in livers of mice with acute liver failure suggested that increased histone H3 acetylation induces the expression of genes related to damage response. Reduced histone acetylation by the histone acetyltransferase inhibitor garcinol decreased liver damage and improved survival in mice with acute liver failure. Knock-down of PDHC or LDH improved viability in cells exposed to a pro-apoptotic stimulus. Treatment with the LDH inhibitor galloflavin that was also found to inhibit PDHC, reduced hepatic necrosis, apoptosis, and expression of pro-inflammatory cytokines in mice with acute liver failure. Mice treated with galloflavin also showed a dose-response increase in survival.
CONCLUSION:
PDHC and LDH translocate to the nucleus, leading to increased nuclear concentrations of acetyl-CoA and lactate. This results in histone H3 hyper-acetylation and expression of damage response genes. Inhibition of PDHC and LDH reduces liver damage and improves survival in mice with acute liver failure. Thus, PDHC and LDH are targets for therapy of acute liver failure.